Alias
科研级 Eptinezumab ( 依普奈珠单抗 ), Anti-CGRP Recombinant Antibody, Research Grade Eptinezumab
Molecular Name
Eptinezumab
Applications
ELISA, IHC, IF, IP, Flow Cyt, Inhibition
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
CALCA /CALCB[Homo sapiens]
Background
Eptinezumab, sold under the brand name Vyepti, is a medication for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion every three months. Eptinezumab-jjmr was approved for use in the United States in February 2020.
Storage
该产品可在 2°C-8°C 下保存一个月,活性不会明显降低。在 -20°C 至 -80°C 下保存,可稳定保存十二个月。避免反复冻融,用冰袋运输。